OraSure (OSUR)

Executive Summary

OraSure Technologies is a global leader in non-invasive diagnostic testing, best known for its OraQuick platform for HIV and HCV detection. The company has undergone a strategic transformation, divesting non-core assets and focusing on its core infectious disease testing and molecular diagnostics. This restructuring has streamlined operations, improved margins, and positioned OraSure for sustainable growth. With a strong product portfolio and a shift towards decentralized and at-home testing, the company is well-positioned to benefit from increasing consumer demand for self-testing solutions. However, competition from rapid antigen tests and regulatory hurdles remain key risks. Looking ahead, OraSure's growth is driven by expansion of its self-testing portfolio, potential FDA approvals for new indications, and international market penetration. The company's molecular diagnostics platform also offers a long-term growth avenue. Despite near-term headwinds from declining COVID-19 testing demand, OraSure's core business remains resilient. The company's focus on innovation and strategic partnerships should support its competitive position in the diagnostics market.

Upcoming Catalysts (preview)

• Q3 2026FDA OTC approval of OraQuick HCV self-test for expanded population70% success
• Q2 2026Launch of new molecular diagnostic assay menu for the Accula platform60% success
• Q4 2026Strategic distribution partnership for emerging markets (e.g., Africa, Asia)50% success